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Abstract
Background: To investigate the prevalence of depression and anxiety among subjects with self-reported glaucoma
and the association between self-reported glaucoma and depression respectively anxiety in a European cohort.
Methods: A study sample of 14,657 participants aged 35 to 74 years was investigated in a population-based cohort
study. All participants reported presence or absence of glaucoma. Ophthalmological examinations were carried out
in all participants and demographic and disease related information were obtained by interview. Depression was
assessed with the Patient Health Questionnaire (PHQ-9), and generalized anxiety with the two screening items
(GAD-2) of the short form of the GAD-7 (Generalized Anxiety Disorder-7 Scale). Prevalence of depression and
generalized anxiety were investigated for subjects with and without self-reported glaucoma. Logistic regression
analyses with depression, respectively anxiety as dependent variable and self-reported glaucoma as independent
variable were conducted and adjusted for socio-demographic factors, systemic comorbidities (arterial hypertension,
myocardial infarction, stroke, diabetes mellitus, chronic obstructive pulmonary disease, cancer), ocular diseases
(cataract, macular degeneration, corneal diseases, diabetic retinopathy), visual acuity, intraocular pressure,
antiglaucoma eye drops (sympathomimetics, parasympathomimetics, carbonic anhydrase inhibitors, beta-blockers,
prostaglandins) and general health status.
Results: 293 participants (49.5% female) reported having glaucoma. Prevalence of depression among participants
with and without self-reported glaucoma was 6.6% (95%-CI 4.1–10.3) respectively 7.7% (95%-CI 7.3–8.2), and for
anxiety 5.3% (95%-CI 3.1–8.7) respectively 6.6% (95%-CI 6.2–7.1). Glaucoma was not associated with depression
(Odds ratio 1.10, 95%-CI 0.50–2.38, p = 0.80) or anxiety (1.48, 95%-CI 0.63–3.30, p = 0.35) after adjustment for socio-
demographic factors, ocular/systemic diseases, ocular parameters, antiglaucoma drugs and general health status. A
restriction to self-reported glaucoma cases either taking topical antiglaucoma medications or having a history of
glaucoma surgery did not alter the result.
Conclusions: This is the first study analyzing both depression and anxiety among glaucoma patients in a European
cohort. Subjects with and without self-reported glaucoma had a similar prevalence of depression and anxiety in our
population-based sample. Self-reported glaucoma was not associated with depression or anxiety. A lack of a burden
of depressive symptoms may result from recruitment from a population-based sample as compared to previous
study groups predominantly recruited from tertiary care hospitals.
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Background
Glaucoma is a chronic, progressive eye disease, which is
characterized by optic nerve damage and visual field loss
[1]. It is the second leading cause of irreversible blind-
ness worldwide [2], with approximately 8 million cases
of bilateral blindness in 2010 [3]. The number of people
with glaucoma was estimated to be 64 million in 2013
[4], increasing to 80 million by 2020 [3]. Treatment
often includes the use of multiple eye drops and surgery,
however, optic nerve damage cannot be reversed and
many patients present disease progression despite ther-
apy. The fear of potential vision loss may result in a
higher prevalence of depression and anxiety among
glaucoma patients compared to the general population.
Depression is a frequent comorbid condition observed
in chronic diseases [5, 6] and consequently it has been
debated in the past years, whether depression is in-
creased in glaucoma patients or not. Several studies
showed a higher prevalence of depressive symptoms
among glaucoma patients [7–11], while Wilson et al. did
not confirm this finding [12]. The prevalence of depres-
sion in subjects with glaucoma has been estimated to be
between 10 and 32% in previous studies [7, 11].
Anxiety frequently co-occurs with depression, and
anxiety disorders may rise in subjects with glaucoma
due to fear of potential blindness and restrictions in
everyday activities [13]. Several community-based stud-
ies analyzed the prevalence of depression [8, 14] in glau-
coma patients, but so far, to the best of our knowledge,
this is the first study analyzing both depression and
anxiety in a European cohort.
The Gutenberg Health Study (GHS) is a population-
based, prospective cohort study in Germany. It includes
physical examinations, interviews and questionnaires,
related to physical and mental health conditions. This
database can be used to determine the prevalence of de-
pression and anxiety among subjects with self-reported
glaucoma, and to identify associated factors modifying
possible relationships between self-reported glaucoma
and psychological disturbances. The results of this study
can be used to improve understanding and awareness of
mental diseases in glaucoma patients.
Methods
The Gutenberg Health Study (GHS) is an ongoing
population-based, interdisciplinary, prospective, observa-
tional single-center cohort study in the Rhein-Main
Region in western mid-Germany. It was approved by the
ethics committee (Ethics Commission of the State
Chamber of Physicians of Rhineland-Palatinate, refer-
ence no. 837.020.07, original vote: 22.3.2007, latest
update: 20.10.2015). According to the Declaration of
Helsinki, written informed consent was obtained from
all subjects before entering the study. The population
sample was randomly drawn via local residents’ registra-
tion offices and equally stratified by sex and residence
(urban/rural) for each decade of age. Exclusion criteria
were physical and mental disability to visit the study
center on their own and an insufficient knowledge of the
German language. A detailed description of the study
design has been published elsewhere [15].
Study sample
The baseline sample of 15,010 participants aged 35 to
74 years of the Gutenberg Health Study (GHS) was ana-
lyzed in this study.
Materials and assessment
The baseline-examination was carried out between 2007
and 2012, lasted 5 h and included evaluation of preva-
lent classical cardiovascular risk factors and clinical
variables, laboratory examinations from a venous blood
sample, blood pressure and anthropometric measure-
ments, as well as ophthalmological examinations and
computer-assisted personal interviews [16].
Ophthalmological examinations
The ophthalmic part was described in detail by Höhn et
al. [16]. In brief, the ophthalmic examinations included
objective refraction and distance-corrected visual acuity
(DCVA) (Humphrey Automated Refractor / Keratometer
[HARK] 599; Carl Zeiss Meditec AG, Jena, Germany)
and intraocular pressure (IOP) (Nidek NT-2000; Nidek,
Co., Gamagori, Japan).
Self-reported eye diseases and history of any form of
glaucoma surgery were assessed by questions during the
eye examination. Participants were asked if they suffer
from glaucoma, cataract, macular degeneration, corneal
diseases or diabetic retinopathy. Additionally, partici-
pants were asked if they used any eye drops. Antiglau-
coma eye drops were classified using the Anatomic
Therapeutic Chemical (ATC) code, including following
substance groups: Sympathomimetics (S01EA), Parasym-
pathomimetics (S01 EB), Carbonic anhydrase inhibitors
(S01EC), Beta-blockers (S01ED), Prostaglandins (S01EE).
Questionnaires
Depression was assessed with the Patient Health Ques-
tionnaire (PHQ-9), which evaluates how often subjects
have been bothered by any of the nine diagnostic criteria
of Major depression over the last two weeks. The total
points for each of the items were summed up to create a
score between 0 and 27 points. Depression was defined
as a sum score of ≥10. A prior study showed a sensitivity
of 81% and a specificity of 82% for any depressive
disorder [17]. In addition, depressive symptoms were
classified as “minimal” (score 5 to 9), “mild” (score 10 to
14), “moderately severe” (score 15 to 19) and “severe”
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(score > 20) [18]. Generalized anxiety was measured with
the two screening items of the short form of the GAD-7
(Generalized Anxiety Disorder [GAD]-7 Scale), a screen-
ing tool for all anxiety disorders. Participants rated
“Feeling nervous, anxious or on edge” and “Not being
able to stop or control worrying” by 0 = “not at all”, 1
= “several days”, 2 = “over half the days”, and 3 = “nearly
every day”. Generalized anxiety (GAD-2) was defined as
a sum score of ≥3, corresponding to a sensitivity of 86%
and a specificity of 83% [19].
Computer-assisted personal interview
During the computer-assisted personal interview sub-
jects were asked if they had the history of any depressive
or anxiety disorder. According to Lampert and Kroll, the
socioeconomic status (SES) was defined by education,
income and job position, with a range from 3 to 21,
while 3 indicated the lowest SES and 21 the highest SES
[20]. For statistical analyses, three groups were defined
including low SES (3–8 points), medium SES (9–14
points) and high SES (15–21 points) [21].Furthermore,
subjects were asked to classify their general health con-
dition into four categories (Excellent = 1, good = 2, fair =
3 and poor = 4), and the following self-reported general
diseases were collected from the personal interview:
arterial hypertension, myocardial infarction, stroke, dia-
betes mellitus, chronic obstructive pulmonary disease
(COPD) and cancer.
Statistical analysis
Descriptive analyses were performed as absolute and
relative proportions for categorical data, mean and
standard deviation for continuous variables with ap-
proximately normal distribution and median with inter-
quartile range if not fulfilling this criterion.
Prevalence rates of depression and depressive symptoms,
resp. generalized anxiety were given for subjects with and
without self-reported glaucoma in our study sample.
To validate self-reported glaucoma data, we conducted
a sensitivity analysis and included only those self-reported
glaucoma subjects, who reported the use of antiglaucoma
drugs or having history of glaucoma surgery. Furthermore,
a subgroup analysis was performed, to evaluate only
glaucoma-subjects with advanced disease. Prevalence of
depression and anxiety was computed for subjects with
and without self-reported glaucoma and a visual acuity
>0.5 logMar in the worse eye. Comparisons between
groups were done with chi-squared-test for categorical
variables and with Mann-Whitney U-test and t-test for
continuous variables.
To determine a relationship between self-reported glau-
coma and depression (caseness: PHQ-9 sum score < 10 vs.
PHQ-9 sum score ≥ 10), resp. generalized anxiety (case-
ness: GAD-2 sum score < 3 vs. GAD-2 sum score ≥ 3) we
performed logistic regression analysis with depression
(PHQ-9 sum score) resp. anxiety (GAD-2 sum score)
as the dependent variable. In model 1, self-reported
glaucoma was included as independent variable, ad-
justed for age, sex and socio-economic status. In the
following models, we additionally adjusted stepwise
for systemic comorbidities (arterial hypertension,
myocardial infarction, stroke, diabetes mellitus,
chronic obstructive pulmonary disease, cancer), ocu-
lar diseases (cataract, macular degeneration, corneal
diseases, diabetic retinopathy), visual acuity of the
worse eye, IOP, antiglaucoma eye drops (Sympatho-
mimetics, Parasympathomimetics, Carbonic anhy-
drase inhibitors, Beta-blockers, Prostaglandins) and
general health status. The last model included all the
above mentioned independent variables.
All p-values should be regarded as a continuous
parameter that reflect the level of statistical evidence
and are therefore reported exactly. Statistical analysis
was carried out using R version 3.3.1 [22].
Results
14,657 (98% of 15,010) subjects were analyzed and 293
(2.0%) reported having glaucoma. Characteristics of the
total study sample and participants with and without
self-reported glaucoma are described in Table 1.
The mean age of subjects with glaucoma was 11 years
older compared to the non-glaucoma group. Subjects
with glaucoma presented more often with a low SES
compared to the non-glaucoma group. General comor-
bidities such as diabetes mellitus, arterial hypertension,
stroke, COPD, bronchial asthma and cancer were more
often seen in the glaucoma-group. For ocular comorbidi-
ties, the distributions were similar in both groups except
for cataract. Mean visual acuity in the worse eye was
relatively good for both groups (0.1 vs. 0 logMar).
Ophthalmological data are presented in Table 2.
There was no difference in the prevalence of depres-
sion between subjects with and without self-reported
glaucoma. The prevalence of depression was 6.6% (95%
CI 4.1–10.3) for participants with self-reported glaucoma
compared to 7.7% (95% CI 7.3–8.2) for participants
without self-reported glaucoma (p = 0.58).
For both groups, the prevalence of severe depression
was very low compared to minimal depressive symptoms
and the distribution of depression severity was comparable
(Table 3). Of the participants with self-reported glaucoma
69.1% presented no depressive symptoms (vs. 64.8%; p =
0.14), 24.3% minimal (vs. 27.5%; p = 0.26), 4.9% mild (vs.
5.8%; p = 0.61), 1.7% moderately severe (vs. 1.5%; p = 0.62)
and 0.0% severe (vs. 0.4%; p = 0.63) depressive symptoms.
With respect to anxiety, prevalence did not differ be-
tween the glaucoma and non-glaucoma group. Preva-
lence for anxiety was 5.3% (95% CI 3.1–8.7) in the
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glaucoma group vs. 6.6% (95% CI 6.2–7.1) in the
non-glaucoma group (p = 0.47) (Table 3).
To validate self-reported glaucoma data, we analyzed
glaucoma defined as self-reported glaucoma and the use
of antiglaucoma eye medications or history of glaucoma
surgery. According to this definition, 333 subjects had
glaucoma. Comparable prevalence of anxiety (5.3% in
the glaucoma group vs. 6.6% in the non-glaucoma group,
p = 0.37) and of depression (7.0% vs. 7.7% in the
non-glaucoma group, p = 0.75) was found (Table 4).
Table 1 Characteristics and general health condition of participants with and without self-reported glaucoma in the Gutenberg
Health Study (GHS), 2007–2012
All (N = 14,657) No self-reported glaucoma
(N = 14,364) mean or %
Self-reported glaucoma
(N = 293) mean or %
P value
Demographics
Age, years 55 55 66 <0.0001
Sex (women) (%) 49.5 49.5 51.2 0.6
SES 12.0 12.0 11.0 0.0001
High (3–8) (%) 18.3 18.1 25.0 0.004
Medium (9–14) (%) 46.2 46.2 48.6 0.4
Low (15–21) (%) 5.5 35.7 26.4 0.001
Comorbidities and general health status
Diabetes mellitus (%) 9.3 9.2 17.1 <0.0001
Arterial hypertension (%) 49.6 49.1 71.7 <0.0001
Myocardial infarction (%) 2.9 2.9 3.8 0.38
Stroke (%) 1.9 1.9 2.4 0.51
COPD (%) 5.0 4.9 8.5 0.01
Bronchial asthma (%) 2.9 2.8 5.5 0.01
Cancer (%) 9.9 8.9 13.7 0.01
General health status 2.11 ± 0.64 2.10 ± 0.64 2.18 ± 0.61 0.03
Excellent (%) 12.7 12.8 7.5 0.01
Good (%) 66.9 66.8 70.2 0.23
Fair (%) 17.4 17.4 18.5 0.64
Poor (%) 12.7 12.8 7.5 0.01
SES socioeconomic status, COPD chronic obstructive pulmonary disease
Table 2 Ocular characteristics of participants with and without self-reported glaucoma in the Gutenberg Health Study (GHS), 2007–2012
All (N = 14,657) No self-reported glaucoma
(N = 14,364) mean or %
Self-reported glaucoma
(N = 293) mean or %
P value
logMar DCVA 0.05 0 0.1 <0.0001
IOP (mmHg) 14 14 15.75 0.0001
Ocular diseases
AMD (%) 0.5 0.5 1.4 0.05
Corneal diseases (%) 2.0 2.0 3.8 0.05
Cataract (%) 30.7 30.3 49.5 <0.0001
Diabetic retinopathy (%) 0.5 0.5 0.7 0.66
Antiglaucoma drugs
Sympathomimetics (%) 0.3 0.0 11.6 <0.0001
Parasympathomimetics (%) 0.0 0.0 1.4 <0.0001
Carbonic anhydrase inhibitors (%) 0.3 0.1 12.6 <0.0001
Beta-blockers (%) 1.4 0.2 61.1 <0.0001
Prostaglandins (%) 0.7 0.0 30.4 <0.0001
IOP intraocular pressure, DCVA distantce-corrected visual acuity
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To identify subjects with an advanced disease, we
performed a subsample analysis between those having a
visual acuity >0.5 logMar in the worse eye. Only 4.1%
(597) of the sample had a visual acuity >0.5 logMar. In
the glaucoma group 8.9% had a visual acuity >0.5%
compared with 4.0% in the non-glaucoma group. Both
prevalence of depression and anxiety were higher for the
non-glaucoma group in this subsample analysis (Table 5).
Prevalence for depression in glaucoma and non-glaucoma
subjects with VA logMar >0.5 were 0 and 8.7% (p = 0.25).
Prevalence for anxiety in glaucoma and non-glaucoma
subjects with VA logMar >0.5 were 4.2 and 5.4% (p = 1.0).
To investigate associations between self-reported glau-
coma and depression, resp. anxiety we performed logis-
tic regression analyses. After adjusting for age, sex and
SES we found no association between self-reported glau-
coma and depression (OR 1.08, 95% CI 0.69–1.62), resp.
anxiety (OR 1.15, 95% CI 0.7–1.78). After additional ad-
justment for general comorbidities (namely arterial
hypertension, diabetes mellitus, myocardial infarction,
stroke, COPD, cancer), visual acuity (worse eye), IOP,
ocular diseases (namely cataract, AMD, corneal diseases,
diabetic retinopathy), antiglaucoma drugs (namely eye
drops categorized into sympathomimetics, carbonic
anhydrase inhibitors, beta-blockers, prostaglandins)
and general health status we also found no associ-
ation (Table 6).
Discussion
This is the first population-based study in a large European
cohort analyzing the association between a) self-reported
glaucoma and depression and b) self-reported glaucoma
and anxiety.
Table 3 Prevalence of anxiety and depression and severity of depressive symptoms in participants with and without self-reported
glaucoma in the Gutenberg Health Study (GHS), 2007–2012
All (N = 14,657) No self-reported glaucoma
(N = 14,364) mean or %
Self-reported glaucoma
(N = 293) mean or %
P-value
Depression
PHQ-9≥ 10 (%) 7.7 7.7 6.6 0.58
History of depression (%) 12.0 12.1 9.6 0.24
None (%) 64.9 64.8 69.1 0.14
Minimal (%) 27.4 27.5 24.3 0.26
Mild (%) 5.8 5.8 4.9 0.61
Moderately (%) 1.5 1.5 1.7 0.62
Severe (%) 0.4 0.4 0.0 0.63
Anxiety
GAD-2≥ 3 (%) 6.6 6.6 5.3 0.47
History of Anxiety (%) 7.3 7.3 6.5 0.65
PHQ-9 Patient Health Questionnaire, GAD-2 Generalized Anxiety Disorder-2 Scale
Table 4 Sensitivity Analysis of participants with new glaucoma definition: Self-reported glaucoma + antiglaucoma drugs and/or
history of glaucoma surgery
All (N = 14,657) No glaucoma (N = 14,324) mean or % Glaucoma (N = 333) mean or % P-value
Depression
PHQ-9≥ 10 (%) 7.7 7.7 7.0 0.75
History of depression (%) 12.0 12.0 10.6 0.49
None (%) 64.9 64.8 69.1 0.11
Minimal (%) 27.4 27.5 23.9 0.15
Mild (%) 5.8 5.8 5.2 0.72
Moderately (%) 1.5 1.5 1.8 0.48
Severe (%) 0.4 0.4 0.0 0.64
Anxiety
GAD-2≥ 3 (%) 6.6 6.6 5.3 0.37
History of Anxiety (%) 7.3 7.3 5.7 0.34
PHQ-9 Patient Health Questionnaire, GAD-2 Generalized Anxiety Disorder Scale
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The present study did not show a higher prevalence of
depression or anxiety in self-reported glaucoma subjects
compared to control subjects and there was no statisti-
cally significant association between glaucoma and
depression or anxiety.
In our study sample the prevalence for depression was
6.6% in the glaucoma group and 7.7% in the
non-glaucoma group. The prevalence for anxiety was
5.3% in the glaucoma group and 6.6% in the
non-glaucoma group.
Prior studies showed a great inconsistency in de-
pression prevalences among subjects with glaucoma.
Depression prevalences varied between 4.3 and 32.1%
[7, 8, 10–12, 14, 23–25]. Anxiety prevalences among
glaucoma patients were reported to be as high as
13.0% in Japan [7], 22.9% in China [25] and 64% in
Singapore [10]. However, it should be noted that
these studies differed in study design, sample size and
study population. For example, Lim et al. [10] showed
depression and anxiety prevalence of 30 and 64%,
which is much higher than in our study and com-
pared to other studies. This study was conducted as a
case-control study with the study population recruited
from tertiary care hospitals. Those studies with sub-
jects recruited from a tertiary care hospital seem to
have higher prevalence rates in general which may be
an overestimation due to increased severity of cases.
Glaucoma patients treated in hospitals present more
often disease progression and complex medical
records and consequently may have a higher risk for
depression or generalized anxiety. Most of the partici-
pants of the GHS probably did not require medical
treatment in a tertiary care hospital due to their glau-
coma disease. Population-based studies have a more
heterogeneous study sample, representative of the
general population. Prevalence for depression in two
other population based studies were 4.3% [14] and
10.9% [8]. It should be considered that an underesti-
mation in a population based study is possible, since
severe depression may prevent subjects from attend-
ing such studies. Regarding the distribution of depres-
sion classes in the current study, there is a low
prevalence of moderately severe and severe depression
in both groups. In the glaucoma and non-glaucoma
group moderately severe depression was seen in 1.7
and 1.5% (p = 0.62) and severe depression in only
0.4% of the non-glaucoma group (p = 0.63). A recent
cross-sectional study evaluating 1520 patients for
glaucoma status, dry eye, mood and sleep disorders
showed similar depression and anxiety rates in the
glaucoma group receiving prostaglandin monotherapy
and the non-glaucoma group. These findings are con-
sistent with our results. The authors assume that so-
cial awareness of glaucoma and advanced diagnostics
Table 5 Subsample Analysis of participants with logMar BCVA>0.5 in the worse eye
All (N = 597) Self-reported no glaucoma (N = 571) mean or % Self-reported glaucoma (N = 26) mean or % P-value
Depression
PHQ-9≥ 10 (%) 8.3 8.7 0.0 0.25
History of depression (%) 13.6 14.3 0.0 0.04
None (%) 59.5 59.2 66.7 0.53
Minimal (%) 32.1 32.1 33.3 1.00
Mild (%) 6.7 7.1 0.0 0.40
Moderately (%) 1.4 1.5 0.0 1.00
Severe (%) 0.2 0.2 0.0 1.00
Anxiety
GAD-2≥ 3 (%) 5.4 5.4 4.2 1.00
History of Anxiety (%) 9.1 9.5 0.0 0.16
PHQ-9 Patient Health Questionnaire, GAD-2 Generalized Anxiety Disorder Scale
Table 6 Associations of self-reported glaucoma with depression and anxiety in the Gutenberg Health Study (GHS), 2007–2012
Model 1 Model 2
OR CI P-Value n OR CI P-Value n
Depression (PHQ-9≥ 10) 1.08 0.69–1.62 0.72 14,359 1.10 0.50–2.38 0.80 14,061
Anxiety (GAD-2≥ 3) 1.15 0.70–1.78 0.55 14,288 1.48 0.63–3.30 0.35 13,991
PHQ-9 Patient Health Questionnaire, GAD-2 Generalized Anxiety Disorder Scale, OR Odds ratio, CI 95% confidence Interval
Model 1: logistic regression analysis adjusted for age, sex, socio-economic status; Model 2 additionally adjusted for systemic comorbidities (arterial hypertension,
myocardial infarction, stroke, diabetes mellitus, chronic obstructive pulmonary disease, cancer), ocular diseases (cataract, macular degeneration, corneal diseases,
diabetic retinopathy), visual acuity of the worse eye, IOP, antiglaucoma eye medications (Sympathomimetics, Parasympathomimetics, Carbonic anhydrase
inhibitors, Beta-blockers, Prostaglandins) and general health status
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tools have led to an improvement in disease manage-
ment and may contribute to the prevention of psychi-
atric disorders in glaucoma patients [26].
Our study provides a wide range of socio-demographic
factors and comorbidities to assess a possible independ-
ent association between glaucoma and depression or
anxiety.
In both groups the prevalence of self-reported cataract
is high, with 49.5% in the glaucoma group and 30.3% in
the non-glaucoma group and might be a confounding
factor. Population-based studies showed that depressive
symptoms and anxiety were associated with self-reported
cataract [14, 27]. However adjusting for ophthalmo-
logical diseases including cataract did not alter our
findings.
We conducted multiple regression analyses to evaluate
a potential relationship. In none of the models could we
find an association between glaucoma and depression or
anxiety. This is consistent with the results of Wang et
al., who also did not observe a significant association
after including self-reported general health condition in
the regression model. Glaucoma was also self-reported
in this population based study [8]. Wilson et al. enrolled
a prospective case-control study and stated that
self-reported glaucoma patients are not more depressed
than patients without glaucoma [12]. The survey instru-
ment used for identifying depression was different from
ours, in contrast to the study of Wang et al., where also
the PHQ-9 was applied. Both are established survey
instruments with a high reliability and validity and useful
screening tests for identifying symptoms of depression
[17, 28]. The results of Wang et al. might suggest that
the perception of having poor general health, induced by
an eye disease may be the causal link between eye
disease and depression. Consistent with their findings,
objective measures of glaucoma such as visual acuity
and visual field defects were not associated with depres-
sion, in contrast to self-reported measures of visual
disability. Self-reported measures were determined from
a validated instrument for self-reporting visual disability
(the National Eye Institute Visual Function Question-
naire). Su et al. also demonstrated a high impact of
systemic comorbidities on depression rates among glau-
coma patients in a case-control study. They compared
glaucoma patients with a diagnosis of depression to age-
and sex-matched glaucoma control subjects without de-
pression. A significantly higher percentage of subjects
with a high comorbidity index score was found in the
depression group (p < 0.0001) [24]. Other previous stud-
ies showed that self-reported measures like General
Health Status, rather than objective parameters were
predictors of depression in glaucoma [8, 11].
The percentage of ß-blockers use is relatively high
(61.1%) in our study. The use of systemic ß-blockers was
proposed to have neuropsychiatric side effects and to be
a possible risk factor for depression [29]. Therefore,
some clinicians presume that glaucoma patients may
have a higher risk of depression due to the side effects of
topically applied ß-blockers [30]. Prior studies could not
find the use of topical β-blockers to be associated with
depression or anxiety in the multivariate logistic regres-
sion model [8, 10, 12, 24]. Presumably the systemic
concentration of topically applied ß-blockers is not suffi-
cient to contribute to psychiatric side effects.
The strength of this present study is the population-
based design, with a large sample size, standardized ex-
aminations and a broad variety of potential confounders.
Furthermore, we used established survey instruments
with high reliability and validity to identify depression
and general anxiety. However, our study also has some
limitations. Due to the population-based study design
the sample size of the glaucoma group is small, com-
pared to the control group. Glaucoma diagnosis was
self-reported, which may lead to recall-error. In our
study design optical coherence tomography (OCT) was
not included. OCT is an imaging technology that can be
used for visualizing and analysing retinal tissue quickly
and noninvasively [31]. It enables the detection of struc-
tural loss in the retinal nerve fiber layer (RNFL) before
perimetric visible visual field defects and has become
standard of care for detection of glaucoma and monitor-
ing its progression and for detecting macular and retinal
diseases [32]. However, we diminished the recall error of
self-reported glaucoma diagnosis by analyzing a sub-
sample, which included only self-reported glaucoma
subjects with an additional use of antiglaucoma medica-
tions or having a history of glaucoma surgery. This sub-
sample analysis revealed similar results. Additional
examination of glaucoma subjects with a visual acuity
>0.5 (logMar) in the worse eye again led to the same
results. Generally, the number of subjects with reduced
visual acuity in our study was low. Only 4.1% (597) of
the total sample had a visual acuity >0.5 in the worse
eye. Subjects with severe visual impairment might not
participate in such a study. This study also comprised
only a small number of participants with severe depres-
sive symptoms. A reason could be that severe depression
prevents subjects from participating in studies. Finally,
the study did not include quantitative visual field
measurements to categorize glaucoma severity. A
categorization by glaucoma severity might reveal dif-
ferent depression and anxiety prevalence in different
glaucoma stages. However, a previous study indicated
that the worse eye’s visual acuity was a stronger
predictor of depression than the mean deviation,
implying that central visual impairment may be more
likely to contribute to depression than peripheral
visual loss [11].
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Conclusions
We did not find participants with self-reported glau-
coma to be more depressed or anxious than participants
without self-reported glaucoma. Adjustment for poten-
tial confounders did not alter our findings substantially.
Future studies are needed to analyze the risk of mental
disorders in glaucoma of different severities.
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